Advanced searches left 3/3

Cardiogenic - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 November 2022

* If you want to update the article please login/register

Study of Microcirculation in Cardiogenic Shock

Low cardiac output low cardiac output results in critical organ hypoperfusion and tissue hypoxia, which is often described as primary cardiac dysfunction. The microcirculation is the terminal vascular network of the systemic circulation composed of microvessels with diameters 20 m including arterioles, capillaries, and venules. This portion of the circulation is vital because it is responsible for nutrient delivery and oxygen exchange from the erythrocytes in the capillaries to parenchymal cells to satisfy their metabolic needs, but it is also the place where water, other gases, hormones, and garbage items are exchanged. Hence, the analysis of clinical signs of peripheral hypoperfusion indicating microvascular perfusion is of utmost importance. This research is also focused on determining the prognosis of these microcirculation parameters and their association with macrocirculation variables such as arterial pressure, heart index, and left ventricular ejection fraction.

Source link: https://clinicaltrials.gov/ct2/show/NCT03436641


A Prospective Randomised Trial of Early LV Venting Using Impella CP for Recovery in Patients With Cardiogenic Shock Managed With VA ECMO

As a haemodynamic rescue strategy in decompensated acute or chronic heart failure, which presents as cardiogenic shock, Veno-arterial extra-corporeal membrane oxygenation is suggested as a haemodynamic rescue scheme. Left ventricular assist devices provide long-term mechanical circulatory assistance and significantly mechanically unload the left ventricle. Mechanical load has been a central role in determining ventricular contractile results across species of humans. Among other things, stimulated de novo cardiomyocyte proliferation, subcellular calcium handling evolution reconstruction, changes to the extracellular matrix of the heart, and reverse remodeling of the neurohormal milleu are among other things. In fact, percutaneous VA-ECMO enhances LV afterload as a result of the retrograde blood circulation, and, as a result of lack of venting, there may be progressive LV distension. In chronic heart failure, prompt ventricular unloading is vital to cardiac recovery. At thirty days, this randomized research seeks to determine whether the introduction of early direct ventricular unloading using Impella CP results in elevated rates of cardiac recovery, defined as survival free from mechanical circulatory assistance, heart transplantation, or inotropic assistance. This research will also investigate the effects of pulmonary congestion, electrochemical, echocardiographic, and radiologic effects of VA ECMO with and without the addition of Impella CP to directly vent the left ventricle to address other pertinent issues such as the effects on pulmonary congestion.

Source link: https://clinicaltrials.gov/ct2/show/NCT03431467


Assessment of ECMO in Acute Myocardial Infarction With Non-reversible Cardiogenic Shock to Halt Organ Failure and Reduce Mortality (ANCHOR)

Patients with AMI and cardiogenic shock also had to show that VA-ECMO support as a result of IABP-mediated therapy in patients with AMI and cardiogenic shock are therefore better outcomes in comparison to optimal medical care alone. Since recent results indicated survival up-to- 50% with ECMO support in this setting, an ethical rescue option to VA-ECMO will nonetheless be offered to monitor patients with cardiogenic shock refractory to conventional medical therapy. Compared to standard medical therapy alone, early VA-ECMO, with IABP support and optimal medical care will have a better outcome in patients with acute myocardial infarction prone to cardiogenic shock. According to the requirements of emergency consent, eligible patients will be randomised, and the patient will be asked to signify for the continuation of the trial as his/her illness allows. Randomization will be possible in centers with extensive expertise in AMI and cardiogenic shock administration, but there will be no on-site ECMO staff capable of establishing ECMO in less than two hours after randomization. Physicians at the non-ECMO center will ensure that the ECMO team is immediately available and that an ICU/CCU bed is available at the ECMO center before randomization. If the patient is randomized to the ECMO arm, the mobile ECMO retrieval team will join the center, activate VA-ECMO, and quickly transfer the patient from VA-ECMO to the ECMO center.

Source link: https://clinicaltrials.gov/ct2/show/NCT04184635


REvaSCUlarization StratEgy of Multivessel Coronary Artery Disease for Patients With Acute Myocardial Infarction Complicated by Cardiogenic SHOCK Undergoing Veno-arterial Extracorporeal Membrane Oxygenator: Randomized-Controlled Trial (RESCUE-SHOCK)

For patients with AMI and CS, the 2013 American College of Cardiology /American Heart Association and the 2017 European Society of Cardiology guidelines recommend using PCI of significant stenosis in non-IRA during a primary procedure to increase overall myocardial perfusion and hemodynamic stability for patients with AMI and CS. However, the 30-day risk of a composite of death or severe renal dysfunction leading to renal transplantation therapy in the immediate multi-vessel PCI group was higher in the immediate multi-vessel PCI group than in the culprit lesion-only PCI group. Despite this, there is also some unresolved question regarding the role of non-IRA revascularization in AMI patients with CS. Patients in the CULPRIT-SHOCK trial may have a mild case of CS and just a few patients received MCS devices. Patients with non-ST-segment elevation MI and CS who do not require MCS, according to the CULPRIT-SHOCK study, the benefits of multi-vessel PCI in patients with non-ST-segment elevation MI and CS were more apparent in those requiring MCS. Several new reports from the Korea Acute Myocardial Infarction National Health Registry showed that multivessel PCI was associated with a reduced risk of all-cause mortality than culprit-only PCI, indicating a potential benefit of nonculprit lesion revascularization during the index hospitalization on long-term clinical findings. However, the new randomized trial found that immediate multi-vessel PCI for AMI and multi-vessel disease with an elevated form of CS patients who require veno-arterial extracorporeal membrane oxygenator (Rose).

Source link: https://clinicaltrials.gov/ct2/show/NCT05527717

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions